Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Covid19

Covid19

Part of SARS-CoV-2 infection

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Covid19

162 trials tracked for Covid19: 40 in phase 3 or 4 and 24 with published results. The most-cited published study has 5523 citations.

162Trials tracked
40Phase 3 & 4
0Recruiting
24With published results
Phase distribution
Phase 4 8 Phase 3 32 Phase 2 37 Phase 1 12 Other / NA 73
  1. Phase 3 Aggrenox To Treat Acute Covid-19 Completed · 5,523 cited
  2. Phase 3 VIR-7831 for the Early Treatment of COVID-19 in Outpatients Completed · 1,087 cited
  3. Phase 3 COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) Completed · 247 cited
  4. Phase 3 Convalescent Plasma in Outpatients With COVID-19 Completed · 210 cited
  5. Phase 3 A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older Completed · 175 cited
  6. Phase 3 Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection Completed · 110 cited
Show 44 more trials
  1. Phase 3 ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 Completed · 110 cited
  2. Phase 3 Immune Modulators for Treating COVID-19 Completed · 68 cited
  3. Phase 3 ACTIV-2: A Study for Outpatients With COVID-19 Completed · 49 cited
  4. Phase 4 Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19 Completed · 43 cited
  5. Phase 3 The Prevent Severe COVID-19 (PRESECO) Study Completed · 43 cited
  6. Phase 4 COVID-19 Vaccination of Immunodeficient Persons (COVAXID) Completed · 42 cited
  7. Phase 3 COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis Completed · 36 cited
  8. Phase 3 Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2) Completed · 20 cited
  9. Phase 4 Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE Completed · 16 cited
  10. Phase 3 Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19 Completed · 12 cited
  11. Phase 4 Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19 Completed · 8 cited
  12. Phase 3 Randomized Open Investigation Determining Steroid Dose Completed · 8 cited
  13. Phase 3 Using BCG to Protect Senior Citizens During the COVID-19 Pandemic Completed · 7 cited
  14. Phase 3 ACTIV-6: COVID-19 Study of Repurposed Medications Completed · 5 cited
  15. Phase 4 Project 2VIDA! COVID-19 Vaccine Intervention Delivery for Adults in Southern California Completed · 4 cited
  16. Phase 3 Contrast Enhanced Ultrasound in COVID-19 Completed · 3 cited
  17. Phase 4 SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine Completed
  18. Phase 3 A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19 Completed
  19. Phase 4 Vaccination for Recovered Inpatients With COVID-19 (VATICO) Completed
  20. Phase 4 Evaluation of Aerosol in a Dental Clinic Completed
  21. Phase 3 Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression Completed
  22. Phase 3 Proxalutamide Treatment for Hospitalized COVID-19 Patients Completed
  23. Phase 3 Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment Completed
  24. Phase 3 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400) Completed
  25. Phase 3 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone) Completed
  26. Phase 3 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine) Completed
  27. Phase 3 STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19 Completed
  28. Phase 3 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600) Completed
  29. Phase 3 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100) Completed
  30. Phase 3 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast) Completed
  31. Phase 3 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Completed
  32. Phase 3 Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial) Completed
  33. Phase 3 Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial) Completed
  34. Phase 3 Convalescent Plasma Collection and Treatment in Pediatrics and Adults Completed
  35. Phase 2 Treatment of Covid-19 With a Herbal Compound, Xagrotin Completed
  36. Phase 2 COVID-19 Anosmia Study Completed
  37. Phase 2 FEnofibRate as a Metabolic INtervention for COVID-19 Completed
  38. Phase 2 Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019 Completed
  39. Phase 2 NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis Completed
  40. Phase 2 Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19 Completed
  41. Phase 2 COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol Completed
  42. Phase 2 COVID-19 Study of Safety and Tolerability of Alvelestat Completed
  43. Phase 2 Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia. Completed
  44. Phase 2 Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19 Completed

Showing the 50 most-cited and recently-updated of 162 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Covid19: what the trials found

Several pharmacological interventions have been evaluated for COVID-19 management. Dexamethasone was associated with clinical improvement of at least 2 points on the WHO-OSCI scale at day 28 7. Sotrovimab (VIR-7831) significantly reduced the number of participants experiencing progression of COVID-19 through day 29 and overall disease progression 16. Ivermectin combined with Doxycycline showed significant results in early clinical improvement, late clinical recovery, and a reduction in clinical deterioration 20.

Vaccine efficacy and safety data are established for several products. The Comirnaty (mRNA) vaccine demonstrated statistically significant seroconversion of IgG antibodies in seronegative individuals and significantly different frequencies of local and systemic reactions 8. The Moderna mRNA-1273 vaccine showed specific neutralizing antibody (NAb) ratios at 12, 24, and 48 weeks 13, with a low incidence of severe adverse events or allergic reactions 14.

Other interventions include Convalescent Plasma, which was evaluated for clinical improvement scores and hospital-free days [1, 18], and Remdesivir 21. Infliximab showed significant results regarding recovery by day 28, clinical status at day 14, and mortality through 28 days 22. Therapeutic heparin did not show statistically significant differences in organ support free days, 28-day mortality, or acute kidney injury 9. Dipyridamole and Aspirin were associated with a reduction in inflammatory markers from baseline to 7 days 15.

Additional interventions include Niagen 11, Metformin 17, and Hydrogen Peroxide, which was evaluated for bacterial colony forming units (CFUs) at various locations 12. Pop-up community vaccination sites were also utilized as an intervention 10.

Recent results — preliminary, needs further review

  • Motivational social support from a nurse resulted in measured physical activity levels of 6.7, 4.8, and 8.6 minutes per day 3.
  • Standard messaging for school districts showed no statistically significant difference in enrollment into weekly testing or overall testing rates 2.
  • Large-scale studies were conducted involving text-messaging 4, surveys 6, and other interventions (NCT04665245) that are not yet corroborated by established data.

For the clinician treating this condition

  • Sotrovimab is associated with a significant reduction in the progression of COVID-19 through day 29 16.
  • Dexamethasone is associated with clinical improvement on the WHO-OSCI scale at day 28 7.
  • The combination of Ivermectin and Doxycycline showed statistically significant improvements in early clinical recovery and reductions in clinical deterioration 20.
  • Infliximab demonstrated significant impacts on mortality through 28 days and clinical status at day 14 22.

AI synthesis of 18 cited trials, updated Jun 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Metformin, fluvoxamine, or ivermectin for non-hospitalized COVID-19 adults in a Phase 3 trial
Infectious Disease Phase III
Metformin, fluvoxamine, or ivermectin for non-hospitalized COVID-19 adults in a Phase 3 trial Metformin Cuts Long Covid Risk by 40%
This randomized controlled trial in 1323 non-hospitalized adults with SARS-CoV-2 infection evaluated metformin, fluvoxamine, or ivermectin v…
A common diabetes pill taken early in Covid infection cuts the odds of developing long-term symptoms by 40%, offering new hope for millions.
CT.gov Apr 24, 2026